Malignant Impex Private Limited
About Malignant Impex Private Limited
Data last updated:
Malignant Impex Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the real estate development and construction segment of the real estate and construction sector. It was incorporated on 11 April 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2017PTC315914. Its GSTIN is 07AAKCM9877G1ZR (Delhi).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ajay Khanna and Garish Kapoor.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 2870 – 73 Pvt No – 15 First Floor Gali No17 Beadon Pura Karol Bagh Main Road, New Delhi, Delhi, India – 110005.
As per the financials filed for FY 2024, the company reported a revenue of ₹23.93 Lakh, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹1.22 Lakh (net margin -5.1%) and EBITDA of -₹99,580 (EBITDA margin -4.2%). Revenue has declined at a compounded annual rate (CAGR) of 46% over three years and 43% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address2870 – 73 Pvt No – 15 First Floor Gali No17 Beadon Pura Karol Bagh Main Road, New Delhi, Delhi, India – 110005
- IndustryReal Estate and Construction, Real Estate Builders & Developers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Malignant Impex Private Limited
The main business activity of Malignant Impex is trade. In detail, this covers retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Malignant Impex Private Limited FY 2025 filings available
Malignant Impex Private Limited reported revenue of ₹23.93 Lakh (up 630% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Malignant Impex Private Limited
Revenue rose 630% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 43%. EBITDA fell 631% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Malignant Impex Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹99,580 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹1.22 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Malignant Impex Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -4.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -5.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Malignant Impex are in the company report.
Financial statements from FY 2018
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Malignant Impex Private Limited
Malignant Impex Private Limited is compared with the companies closest to it by revenue in the Real Estate industry (Builders and Developers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nivaan Infralab Private Limited | ₹23.99 Lakh (FY 2025) | •••• | •••• | 23890.0% | •••• | Delhi, India |
| Alliance Elite Homes Private Limited | ₹23.98 Lakh (FY 2023) | •••• | •••• | •••• | Bangalore, Karnataka, India | |
| Siddhee Vinayak Infrahome Private Limited | ₹23.98 Lakh (FY 2025) | •••• | •••• | -73.0% | •••• | Varanasi, Uttar Pradesh, India |
| Saagar Stock Agent Private Limited | ₹23.96 Lakh (FY 2025) | •••• | •••• | 103.0% | •••• | Mumbai, Maharashtra, India |
| Swagatam Distributer Private Limited | ₹23.96 Lakh (FY 2024) | •••• | •••• | -36.0% | •••• | Kolkata, West Bengal, India |
| Malignant Impex Private Limited this company | ₹23.93 Lakh (FY 2024) | •••• | •••• | 630.0% | •••• | New Delhi, Delhi, India |
| Vijkos Construction Private Limited | ₹23.93 Lakh (FY 2019) | •••• | •••• | -79.0% | •••• | Delhi, India |
| Omo Properties Private Limited | ₹23.92 Lakh (FY 2025) | •••• | •••• | -2.0% | •••• | Bangalore, Karnataka, India |
| Fine Finish Construction Private Limited | ₹23.91 Lakh (FY 2025) | •••• | •••• | 9.0% | •••• | Indore, Madhya Pradesh, India |
| DTS Housing and Projects Private Limited | ₹23.9 Lakh (FY 2025) | •••• | •••• | -29.0% | •••• | New Delhi, Delhi, India |
| Lala Builders and Developers Private Limited | ₹23.9 Lakh (FY 2022) | •••• | •••• | 204.0% | •••• | Jaipur, Rajasthan, India |
Peers are the five companies nearest above and the five nearest below Malignant Impex by revenue in the Real Estate industry (Builders and Developers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Malignant Impex Private Limited
Auditor information for Malignant Impex Private Limited provides details about the firm responsible for auditing the company's financial statements and ensuring compliance with regulatory requirements.
Board of Directors of Malignant Impex Private Limited
Malignant Impex has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ajay Khanna | Director | 11 Apr 2017 | 9 Years 5 Months | Current |
| Garish Kapoor | Director | 11 Apr 2017 | 9 Years 5 Months | Current |
Ownership and Shareholding of Malignant Impex Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Malignant Impex Private Limited
Malignant Impex Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Malignant Impex Private Limited
Employment history and EPFO contributions of people linked to Malignant Impex.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Malignant Impex Private Limited
Malignant Impex Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Ajay Khanna was appointed as Director on 11 Apr 2017.
Credit Ratings, Litigation & Regulatory Alerts for Malignant Impex Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Malignant Impex Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Malignant Impex Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Malignant Impex Private Limited
Malignant Impex has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAKCM9877G1ZR | Delhi | Active | 17 Oct 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Malignant Impex Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Malignant Impex Private Limited
Malignant Impex is an active private limited company based in New Delhi, Delhi, India. The company works in real estate builders and developers, within the real estate and construction industry. It was incorporated on 11 April 2017 (9+ years old) and is registered under CIN U51909DL2017PTC315914.
Malignant Impex reported revenue of ₹23.93 Lakh for FY 2024 (up 630% YoY).
Malignant Impex has 2 current directors:
- Ajay Khanna - Director
- Garish Kapoor - Director
Malignant Impex reported a net loss of ₹1.22 Lakh (net margin -5.1%) and EBITDA of -₹99,580 (EBITDA margin -4.2%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Malignant Impex is 46% over three years and -43% over five years. In the latest year (FY 2024) revenue rose 630%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Malignant Impex is 07AAKCM9877G1ZR, registered in Delhi.
The CIN (Corporate Identification Number) of Malignant Impex is U51909DL2017PTC315914. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Malignant Impex was incorporated on 11 April 2017, making it 9+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Malignant Impex by revenue are Nivaan Infralab Private Limited, Alliance Elite Homes Private Limited, Siddhee Vinayak Infrahome Private Limited, Saagar Stock Agent Private Limited, Swagatam Distributer Private Limited and 5 more, all in the Real Estate industry (Builders and Developers).
Ajay Khanna was appointed as Director on 11 Apr 2017. Garish Kapoor was appointed as Director on 11 Apr 2017.
The registered office of Malignant Impex is at 2870 – 73 Pvt No – 15 First Floor Gali No17 Beadon Pura Karol Bagh Main Road, New Delhi, Delhi, India – 110005.